The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The long tail of significantly mutated genes in prostate cancer.
 
Joshua Armenia
No Relationships to Disclose
 
Stephanie Anne Mullane
No Relationships to Disclose
 
JianJiong Gao
No Relationships to Disclose
 
Debyani Chakravarty
No Relationships to Disclose
 
Ritika Kundra
No Relationships to Disclose
 
Franklin W. Huang
No Relationships to Disclose
 
G. Celine Han
No Relationships to Disclose
 
Dan Robinson
No Relationships to Disclose
 
Levi A. Garraway
Stock and Other Ownership Interests - Foundation Medicine
Honoraria - Bayer
Consulting or Advisory Role - Boehringer Ingelheim; Foundation Medicine; Novartis; Third Rock Ventures; Warp Drive Bio
Research Funding - Astellas Pharma; GlaxoSmithKline; Novartis
Travel, Accommodations, Expenses - Bayer; Novartis; Wuxi AppTec
 
Peter Nelson
No Relationships to Disclose
 
Mark A. Rubin
No Relationships to Disclose
 
Mary-Ellen Taplin
Honoraria - Bayer; Dendreon; Janssen-Ortho; Medivation; Tokai Pharmaceuticals
Consulting or Advisory Role - Bayer; Best Doctors, Inc; Clovis Oncology; Dava Oncology; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen-Ortho; Medivation; Parexel; Research to Practice; Sanofi; Tokai Pharmaceuticals; UpToDate
Research Funding - Bayer; Genentech; Janssen-Ortho; Medivation; Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dendreon; Janssen Oncology; Medivation; Tokai Pharmaceuticals
 
Wassim Abida
Honoraria - CARET
Consulting or Advisory Role - Clovis Oncology
Research Funding - AstraZeneca; Zenith Epigenetics
 
Charles L. Sawyers
Leadership - Novartis
Stock and Other Ownership Interests - Agios; BeiGene; Blueprint Medicines; Novartis; ORIC Pharmaceuticals
Consulting or Advisory Role - Agios; BeiGene; Blueprint Medicines; Novartis; ORIC Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Xtandi
 
Arul M. Chinnaiyan
No Relationships to Disclose
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; Druggablity Technologies; Metamark Genetics; Placon; Tarveda Therapeutics
Consulting or Advisory Role - Astellas Pharma; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Cristal Therapeutics; Druggablity Technologies; Endocyte; Genentech/Roche; GTx; Ipsen; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MorphoSys; MTG Therapeutics; Omnitura; OncoCellMDX; Oncogenex; Pfizer; Progenity; Sanofi; Sotio; Tarveda Therapeutics; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Expert Testimony - Janssen; Sanofi
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Sanofi
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Nikolaus Schultz
No Relationships to Disclose
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - Syapse
Consulting or Advisory Role - Novartis; Roche; Syapse; Takeda; Third Rock Ventures
Research Funding - Bristol-Myers Squibb